Last Updated: 23/03/2023
Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine plus dihydroartemisinin-piperaquine to reduce adverse pregnancy outcomes and prevent malaria in Papua New Guinea: a randomised controlled trial
Objectives
To substantially improve health outcomes for women and babies in Papua New Guinea and beyond.
Principal Institution
Principal Investigators / Focal Persons
Rationale and Abstract
Millions of pregnancies are complicated by malaria worldwide. Monthly sulphadoxine-pyrimethamine (SP) treatments, the current treatment strategy, no longer protects from malaria but improves birth outcomes through non-malarial effects. Dihydroartemisinin-piperaquine clears malaria but babies are smaller compared to women who received SP. A clinical trial of their combination has potential to substantially improve health outcomes for women and babies in Papua New Guinea and beyond.
External reference
Thematic Categories
Date
Jan 2022 — Dec 2025
Total Project Funding
$2.14M
Funding Details
National Health and Medical Research Council (NHMRC) Australia, Australia
Grant number: 2000780
Project Site
